Asklepios Kliniken GmbH is a German hospitals company, one of Germany's three largest operators of private hospitals. It employs more than 45,000 people, and owns 150 hospitals worldwide. Asklepios Kliniken was founded by German billionaire Bernard Broermann, who opened his first hospital in 1984.

During the past decade, Asklepios Kliniken Hamburg GmbH conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 6 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Asklepios Kliniken Hamburg GmbH" #1 sponsor was "Celgene" with 8 trials, followed by "Zealand Pharma" with 3 trials sponsored, "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 2 trials sponsored, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials sponsored and "CytoSorbents, Inc" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Asklepios Kliniken Hamburg GmbH" #1 collaborator was "Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)" with 2 trials as a collaborator, "Astellas Pharma Global Development, Inc." with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator, "German Testicular Cancer Study Group" with 1 trials as a collaborator and "Heart Center Leipzig - University Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Asklepios Kliniken Hamburg GmbH" are "Crohn Disease" (5 trials), "Acute Myeloid Leukemia" (3 trials), "Short Bowel Syndrome" (3 trials), "Crohn's Disease" (2 trials) and "Myelodysplastic Syndrome With Excess Blasts-2" (2 trials). Many other conditions were trialed in "Asklepios Kliniken Hamburg GmbH" in a lesser frequency.

Most popular intervention types in "Asklepios Kliniken Hamburg GmbH" are "Drug" (21 trials), "Other" (3 trials), "Device" (2 trials), "Procedure" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "GED-0301" (3 trials), "Ozanimod" (3 trials), "RPC1063" (2 trials) and "glepaglutide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Asklepios Kliniken Hamburg GmbH" are 25 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Asklepios Kliniken Hamburg GmbH". undefined are not yet recruiting, 10 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 9 completed trials in Asklepios Kliniken Hamburg GmbH, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Asklepios Kliniken Hamburg GmbH, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".